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Abstract 
 
Objective:  Cardiovascular disease is the leading cause of death in kidney transplant 
recipients (KTRs), yet incompletely accountable by traditional risk factors.  Inflammation is 
an unconventional cardiovascular risk factor, with gut-derived endotoxemia potentially 
driving inflammation and endothelial disease.  Comparable data are lacking in kidney 
transplantation.  This study investigated the associations of endotoxemia with inflammation, 
endothelial activation, and 5-year cardiovascular events in KTRs.  Determinants of 
endotoxemia were also explored. 
Design, Setting and Subjects:  This is a single-centre cross-sectional study with prospective 
follow-up from a prevalent cohort of 128 KTRs. 
Main Outcome Measures:  Demographic, nutritional and clinical predictors of inflammation 
(high-sensitivity C-reactive protein; hsCRP), endothelial activation (sE-selectin) and 
endotoxemia (endotoxin) were assessed.  Follow-up data on 5-year cardiovascular event rates 
were collected. 
Results:  Endotoxemia (p=0.03), reduced 25-hydroxyvitamin D (p=0.04), high fructose 
intake (p<0.001), decreased fibre intake (p<0.001), and abdominal obesity (p=0.002) were 
independently associated with elevated hsCRP.  In turn, endotoxemia (p=0.007) and 
increasing hsCRP (p=0.02) were both independently associated with raised sE-selectin.  
Furthermore, endotoxemia predicted increased cardiovascular event rate (p=0.02), 
independent of hsCRP and a global measure of cardiovascular risk estimated by a validated 
algorithm of 7-year risk for major adverse cardiac events in kidney transplantation.  
Determinants of endotoxemia included reduced 25-hydroxyvitamin D (p<0.001), 
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hypertriglyceridemia (p<0.001), increased fructose intake (p=0.01), and abdominal obesity 
(p=0.01). 
Conclusions:  Endotoxemia in KTRs contributes to inflammation, endothelial activation, and 
increased cardiovascular events.  This study highlights the clinical relevance of endotoxemia 
in KTRs, suggesting future interventional targets. 
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Introduction 
 
Cardiovascular disease (CVD) is a leading cause of death and a major driver of graft loss in 
kidney transplant recipients (KTRs) 1.  Conventional cardiovascular risk factors incompletely 
explain the increased incidence of cardiovascular events in KTRs 2, and several studies have 
highlighted the potential contributions of non-traditional exposures 2-4.  Inflammation and 
immune reactivity are believed to provoke atherogenesis in the general population 5, whilst 
inflammation correlates with endothelial dysfunction and accelerated atherosclerosis in 
general 6 and chronic kidney disease (CKD) 6-9 populations.  Although less studied in KTRs, 
recent evidence confirms that inflammation is an important and reproducible risk factor for 
cardiovascular events, all-cause mortality, and graft failure among KTRs 2,10-15. 
 
Despite its undisputed clinical significance, factors contributing to inflammation in KTRs 
remain under-investigated.  It is also unclear whether such adverse outcomes are due to 
inflammation per se, or whether it reflects the underlying drivers of inflammatory processes.  
Abdominal obesity and smoking were identified in one study as important modifiable 
determinants of inflammation among KTRs 12, but aside from this, data in kidney 
transplantation remains limited.  Yet studies in general and other diseased populations have 
identified important factors contributing to inflammation and endothelial dysfunction, with 
the role of systemic endotoxemia in this context having received attention recently.   
 
Endotoxemia is characterised by the presence of endotoxins in the blood.  Endotoxin, also 
known as Lipid A, is a core component of lipopolysaccharide (LPS) found in the outer cell 
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membrane of the cell wall of Gram-negative bacteria that reside in the intestinal lumen as 
part of gut microbiota 16.  Upon release into the circulation, LPS stimulates the release of pro-
inflammatory cytokines and expression of surface adhesion molecules such as CD14 on 
inflammatory cells, resulting in the ‘syndrome’ of systemic inflammation 17.  In vitro, 
endotoxin induces endothelial damage and activation 16.  Clinical data shows that systemic 
endotoxemia is associated with cardiovascular disease in the general population 18, 
atherosclerosis in patients undergoing peritoneal dialysis 19, and increased mortality risk in 
haemodialysis patients 20,21.  The association between CD14 and mortality in CKD 22 and 
haemodialysis cohorts 23,24 further lend support to these observations.  However, the role of 
endotoxemia driving inflammation and endothelial damage among KTRs remains unexplored 
and warrants further investigation. 
 
This study therefore set out to investigate the role of endotoxemia on inflammation and 
endothelial activation in clinically stable KTRs, alongside traditional cardiovascular risk 
factors and contemporary risk factors such as hypovitaminosis D 25-28, hyperuricemia 29-31, 
hypoadiponectinemia 32-34, and high dietary intake of fructose 35-37.  The association between 
endotoxemia and 5-year cardiovascular events was also assessed.  Finally, determinants of 
endotoxemia were explored, in an attempt to shed new light on plausible interventional 
targets to improve cardiovascular outcome in kidney transplantation. 
 
Methods 
 
Participants and Study Design 
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This is a cross-sectional study with prospective follow-up from a prevalent cohort of KTRs 
beyond 1-year post-transplantation with stable graft function (<10% increase in serum 
creatinine over the preceding 6 months).  Patient recruitment occurred between April 2010 
and April 2013.  Exclusion criteria included episodes of acute rejection within the last 6 
months, evidence of sepsis in the last 6 weeks, known active malignancy or chronic infection, 
history of thyroid disease or adrenal insufficiency, and contraindications for use of 
bioimpedance-based body composition assessment (i.e. implanted or external electronic 
devices, metallic implants, amputations, pregnancy, and lactation).   This study was approved 
by the local research ethics committee and was conducted in accordance with the Declaration 
of Helsinki. 
 
Data Collection 
 
Demographic and Clinical Parameters 
 
Age, gender, ethnicity, and time post-transplantation were collected from patients’ medical 
records.  Alcohol intake (units per week) and smoking status were collected by questionnaire.  
Smoking status were classified into non-smoker, ex-smoker and current smoker, with ex-
smokers defined as individuals who had ever smoked but did not smoke at the time of 
research visit, regardless of their age and length of time since quitting 38.  In addition, the 
following clinical parameters were retrieved from patients’ medical records:  1) presence of 
coronary heart disease; 2) presence of diabetes, either pre-transplantation (pre-DM), or new 
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onset diabetes after transplantation (NODAT); 3) previous acute rejection episodes; 4) 
dialysis vintage; 5) number of kidney transplants; 6) pre-emptive transplantation; 7) use of 
statin; and 8) immunosuppressive medication usage, either prednisolone, calcineurin inhibitor 
(CNI), or adjunctive antiproliferative agent.  Comorbidity was assessed by Index of 
Coexistent Disease (ICED) using the algorithm described by the Haemodialysis Study 39.  
Cardiovascular risk was estimated by 7-year risk for major adverse cardiac events (MACE) in 
kidney transplantation using a validated algorithm derived by Soveri et al 40,41.  The required 
data for calculations of ICED and 7-year risk for MACE were extracted from patients’ 
medical records.   
 
Systolic (SBP) and diastolic (DBP) blood pressure were measured semi-recumbent with a 
fully automatic upper-arm digital blood pressure monitor (Spot Vital Signs LXi; Welch 
Allyn).  Six readings over an 8- to 10- minute period were taken, with the first reading 
ignored, and the mean of the remaining five used for subsequent derivation of mean arterial 
pressure (MAP), calculated using the formula (2DBP+SBP)/3 42.   
 
Cardiovascular Event Data 
 
Following data collection at initial study evaluation, time to cardiovascular event of acute 
origin (i.e. coronary artery disease including acute coronary syndrome or myocardial 
infarction; and cerebrovascular disease including transient ischaemic attack or 
cerebrovascular accident) was extracted from patients’ medical records.  Such events were 
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classified according to clinical presentation at the time of occurrence.  Follow-up period was 
up to 5 years post initial evaluation.  
 
Laboratory Parameters 
 
Blood samples were taken in the morning following an overnight fast for measurements of 
creatinine, estimated glomerular filtration rate (eGFR; derived using four-variable 
modifications of diet in renal disease equation), urate, 25-hydroxyvitamn D, and full lipid 
profile including total cholesterol, high-density lipoprotein (HDL), low-density lipoprotein 
(LDL) and triglycerides.  Analyses were undertaken in the accredited hospital biochemistry 
laboratory.   
 
hsCRP was measured using a Tina-quant® cardiac C-reactive protein latex high sensitive 
immunoturbidimetric assay (Roche Diagnostics, Basel, Switzerland).  The intra- and inter- 
assay coefficients of variations were <1.3% and <5.7% respectively. 
 
Adiponectin and sE-selectin, the latter chosen as the most specific circulating marker for 
endothelial activation 43, were measured using commercially available enzyme-linked 
immunosorbent assay according to manufacturer’s instructions.  The intra- and inter- assay 
coefficients of variation were 3.4% and 5.7% respectively for adiponectin (Linco Ltd, USA) 
44; and <5% and <10% respectively for sE-selectin (R&D Systems, Germany).  
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Serum endotoxin was analysed using a commercially available QCL-1000 Limulus 
Amebocyte Lysate end point assay (Lonza, USA), which has been widely validated as 
detailed previously 45,46.  The intra- and inter- assay coefficients of variation were 3.9% and 
9.6% respectively 47. 
 
Anthropometric Measurements and Body Composition Parameters 
 
Body weight (kg) and height (m) were measured in a standardised procedure with 
participants wearing light clothing without shoes.  Body weight was measured using a digital 
scale to the nearest 0.01kg.  Body height was measured using a stadiometer with the 
participants standing without shoes and feet together, to the nearest 0.01m.  Body mass index 
(BMI, kg/m2) was calculated as weight (kg) divided by height squared (m2).  Waist 
circumference (WC, cm) was measured with a non-stretchable standard tape measure, to the 
nearest 1cm.  It was positioned over the unclothed abdomen at the midpoint of the lower 
thoracic cage and iliac crest in the midaxillary line, as recommended by the World Health 
Organisation 48. 
 
In addition, a well-validated multi-frequency bio-impedance based body composition monitor 
49 (BCM, Fresenius Medical Care, Germany) was used to assess body composition.  
Measurements were carried out in a standard manner while the patient was lying supine in a 
flat and non-conductive bed.  The inbuilt physiological body composition model measures 
whole-body bio-impedance spectroscopy at 50 frequencies (5-1000 kHz) via electrodes 
placed on the wrist (proximal to the transverse) and ankle (arch on the superior side of the 
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foot).  Body composition data including lean tissue index (LTI, kg/m2), fat tissue index (FTI, 
kg/m2), and volume expansion (%) were displayed after each measurement.        
 
Dietary Intake Parameters 
 
Fructose, dietary fibre, total fat and saturated fat intakes were estimated by a 3-day food 
diary, a widely accepted dietary assessment tool deemed to be valid, reliable and accurate in 
estimating typical and habitual nutrient intake 50,51.  Participants were given detailed written 
instructions on completing an accurate dietary record for a 3-day period, which included one 
weekend day, within 1 week before attending the research visit.  These instructions were 
accompanied by verbal explanation from the researcher, which included training in portion 
size estimation and documentation for both dining in and eating out.  The dietary records 
were reviewed by the researcher for accuracy and completeness at the research visit.  Data 
was entered into Dietplan 6 P3 (Forestfield Software Ltd) nutrition analysis program by the 
same researcher, avoiding inter-observer variation.  Total intakes of all nutrients were 
calculated by this program. 
 
Statistical Analysis 
 
Statistical analyses were performed using SPSS Statistics 23 (Chicago, IL).  Results were 
presented as mean ± standard deviation (SD) for normally distributed data or median 
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(interquartile range, IQR) for non-normally distributed data.  Independent-sample t-test was 
used to compare continuous data between groups.   
 
Linear regression analysis was used to determine the associations between predictor variables 
and the continuously distributed outcome variables.   Regression diagnostics were performed.  
The continuously distributed outcome variables (hsCRP, sE-selectin and endotoxin levels) 
demonstrated positively skewed non-Gaussian distributions, logarithmic transformations 
were performed prior to regression analyses.  Time to cardiovascular event data was analysed 
by Cox regression, with Kaplan-Meier survival estimates for the relationship between 
endotoxemia and time to cardiovascular event evaluated by log-rank statistics.  The ranges of 
endotoxin concentrations presented in the Kaplan Meier survival curve were tertiles 
determined following a post-hoc analysis.      
 
The analyses were performed in two stages.  Initially, the effect of each variable was 
examined in a series of univariate analyses.  Subsequently, the joint effect of variables was 
examined in a multivariate analysis, using a backwards selection procedure to derive the final 
model.  A type 1 error rate ≤5% (p≤0.05) was considered significant.  In the multivariate 
regression analyses, only the explanatory variables with univariate p-values of <0.20 were 
included. 
 
Due to logarithmic transformation of the outcome variable, exponential of the beta coefficient 
has been applied, and hence beta coefficient and its associated 95% confidence interval (CI) 
have been transformed and reported in the form of “Ratio”.  For the categorical variable, the 
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ratio of the outcome in each category was relative to the outcome of the baseline category.  
For the continuous variable, unless otherwise stated, the ratio was given for one-unit increase 
in the explanatory variable. 
 
Graphical linear and non-linear associations shown in Figure 1, Figures 2a-2b, and 
Supplementary Material were determined by GraphPad Prism version 6 (GraphPad 
Software, La Jolla California, USA) using either linear regression, exponential model, or 
second order polynomial (quadratic) lines of best fit. 
 
Results 
 
Patient Characteristics 
 
Of 138 patients approached, 10 did not participate due to work commitment (93% consent 
rate).  Mean age was 49 ± 15 years, 56% were male, 78% were Caucasian, 29% and 9% were 
ex-smoker and current smoker respectively, 20% had either pre-DM or NODAT, mean eGFR 
was 48 ± 18 mL/min, and mean SBP and DBP were 140 ± 19 and 80 ± 10 mmHg 
respectively.  Immunosuppressive medication usage among KTRs were:  78% on 
prednisolone; 91% on calcineurin inhibitor; and 87% on adjunctive antiproliferative agent.  
Statin usage was 55%.  Median endotoxin level was 1.95 (1.49 – 2.38) EU/mL.  Median 
hsCRP level was 2.47 (1.00 – 4.89) mg/L.  Median sE-selectin level was 34.2 (24.1 – 44.8) 
ng/mL.  Full details of patient characteristics of the studied population are shown in Table 1.   
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Determinants of Inflammation (hsCRP) in KTRs 
 
Table 2 indicates the predictors of inflammation in KTRs.  Increased endotoxin 
concentration was an independent predictor of hsCRP in the final multivariate regression 
model (p=0.03).  Figure 1, shows the relationship between hsCRP and serum endotoxin 
concentration, demonstrating the marked increase in hsCRP with endotoxin level above 2.5 
EU/mL.  Other independent predictors of hsCRP included decreased 25-hydroxyvitamn D 
levels (p=0.04; Supplementary Material, Figure S1a), high fructose intake (p<0.001; 
Supplementary Material, Figure S1b), decreased dietary fibre intake (p<0.001; 
Supplementary Material, Figure S1c), and increasing WC (p=0.002; Supplementary 
Material, Figure S1d). 
	
In addition, univariate associations between the following predictor variables and hsCRP 
were seen, but did not hold in the adjusted model:  increasing urate concentrations (p=0.007), 
increased LDL (p=0.01), higher saturated fat intake (p=0.03) and increased FTI (p<0.001). 
 
Of note, a substantial proportion of the variation in hsCRP was explained by the variables 
contained within the final model (R2=67%). 
 
Determinants of Endothelial Activation (sE-selectin Levels) in KTRs 
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Predictors of sE-selectin levels are detailed in Table 3.  Both increased endotoxin and raised 
hsCRP levels were independent predictors of elevated sE-selectin levels in the multivariate 
regression analysis (p=0.007, Figure 2a; and p=0.02, Figure 2b respectively).  Other 
significant independent predictors included lower adiponectin concentrations (p=0.004; 
Supplementary Material, Figure S2a), higher WC (p=0.005; Supplementary Material, 
Figure S2b), raised MAP (p=0.006; Supplementary Material, Figure S2c), and male 
gender (p=0.01).  In addition, some evidence for an effect of increasing age (p=0.07) and use 
of CNI (p=0.06) were seen in the final model. 
 
Univariate associations with sE-selectin were also seen with decreased HDL (p=0.02), 
increased triglycerides (p=0.001), higher fructose intake (p=0.04), and lower LTI (p=0.004), 
However, these associations did not persist in the adjusted model. 
  
The variables within the final regression model explained 47% of the variation in sE-selectin 
levels (R2=46%). 
 
Determinants of Endotoxin Levels in KTRs 
 
Table 4 shows the predictors of endotoxemia.  Independent predictors of increased endotoxin 
concentrations in the final multivariate regression model were as follows:  decreased 25-
hydroxyvitamn D levels (p<0.001; Supplementary Material, Figure S3a), higher 
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triglycerides (p<0.001; Supplementary Material, Figure S3b), higher fructose intake 
(p=0.01; Supplementary Material, Figure S3c), and increasing WC (p=0.01; 
Supplementary Material, Figure S3d).  Borderline effects of reduced LTI (p=0.07), pre-
DM and NODAT (p=0.08) were seen in the final model. 
 
Univariate associations between increased serum endotoxin concentration and decreased 
HDL (p=0.006), increased LDL (p<0.001), raised total cholesterol (p=0.004), higher intake of 
saturated fat (p=0.04), and increased FTI (p<0.02) were also seen, but did not persist in the 
adjusted model. 
 
The predictor variables within the final regression model explained 46% of the variation in 
endotoxin levels (R2=46%). 
 
Association between Endotoxemia and Cardiovascular Events 
 
Following initial evaluation, all patients underwent prospective follow-up at the same centre 
for a median duration of 51 (IQR 48-58) months.  Six patients suffered an acute 
cardiovascular event during the follow-up period (acute coronary syndrome=3; myocardial 
infarct=1; ischaemic cerebrovascular accident=1; new onset lower limb claudication=1).  
Endotoxin levels were significantly higher in these patients compared to those without 
cardiovascular event during the follow-up period (2.85±0.26 EU/mL versus 1.95±0.06 
EU/mL respectively; p<0.001).  Univariate Cox regression analysis revealed a significant 
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association between endotoxin level and time to cardiovascular event (Hazard Ratio, HR, per 
EU/mL=2.34, 95% CI=1.23, 4.44, p=0.01).  This analysis was then adjusted for hsCRP and 
7-year risk of MACE, the latter as a validated composite surrogate for global cardiovascular 
risk 40,41.  Following adjustment, endotoxin level remained a significant independent predictor 
of cardiovascular event (HR per EU/mL=2.22, 95% CI=1.11, 4.43, p=0.02); 7-year risk of 
MACE also showed a significant independent relationship with time to cardiovascular event 
(HR per %=1.04, 95% CI=1.01, 1.08, p=0.04).  No evidence of an association with hsCRP 
was seen in the adjusted analysis (HR per mg/L=1.01, 95% CI=0.94, 1.08, p=0.87).  Kaplan-
Meier survival estimates for the relationship between endotoxemia (by tertile) and time to 
cardiovascular event are shown in Figure 3.   
 
Discussion 
 
Although the adverse impact of inflammation on patient and graft outcomes in KTRs is well-
recognised, the drivers of such inflammatory responses are incompletely understood, 
therefore impeding the development of therapeutic strategies.  Similarly, the relationship 
between inflammation and vascular disease is subject to confounders by its underlying 
causes, many of which remain unexplored in kidney transplantation.  This study aimed to 
clarify these relationships by exploring the plausible underlying mechanisms, pointing 
towards potential therapeutic targets. 
 
This study represents the first evidence in kidney transplantation showing that endotoxemia 
may be a significant independent predictor of inflammation in KTRs.  This finding extends 
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the relationship observed in non-transplant CKD 20, haemodialysis 20, and peritoneal dialysis 
19 populations.  In addition, endotoxemia was identified as a possible independent risk factor 
for endothelial activation in this study, a novel finding in kidney transplantation.  
Furthermore, this study provides preliminary insight in kidney transplantation that raised 
endotoxin levels may be associated with increased cardiovascular events, an effect 
independent of inflammation or global cardiovascular risk.  However, it is important to note 
that the cardiovascular event rates were low in this study, therefore this finding needs to be 
validated in larger cohort with longer follow-up duration.  Nevertheless, such observations 
are noteworthy in light of the increased cardiovascular risk seen in KTRs, and yet 
incompletely explained by traditional cardiovascular risk factors.  Of clinical relevance, these 
results provide insights for potential therapeutic options.  In addition, it suggests for the first 
time in kidney transplantation that increased dietary intakes of fructose and saturated fats, 
higher waist circumference, and reduced levels of 25-hydroxyvitamin D are possible drivers 
of endotoxemia in this context.  The findings from this study support and extend data from 
the haemodialysis literature, showing potential associations between endotoxemia and high 
BMI 21 as well as elevated triglyceride levels 23.  Collectively, these findings suggest novel 
targets modifiable by dietary and lifestyle interventions. 
 
In vitro study demonstrates the phenomenon of endotoxin-induced endothelial activation and 
dysfunction 16.  This is in line with the current study showing that endotoxin levels were 
positively correlated with levels of circulating sE-selectin, the most specific circulating 
marker of endothelial activation 43, with the latter being independently associated with 
incident coronary artery disease and the presence of carotid atheroma in general populations 
52.  The current study also extends this clinical data to a transplant cohort, whereby an 
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association between endotoxemia and increased cardiovascular events of acute origin was 
observed.  Importantly, this association was independent of a validated composite marker of 
global cardiovascular risk, as previously derived by Soveri et al 40,41.  Pertinently, this 
composite marker was also independently associated with cardiovascular events, supporting 
the face validity of our findings.  Such effect of endotoxemia observed in this study was also 
independent of inflammation, although a systemic inflammatory response, assessed by 
hsCRP, was also in itself associated with elevated sE-selectin levels.  The ‘inflammation-
independent’ effect of endotoxemia upon endothelial activation found in this study resonates 
with a recently described mechanism, whereby endotoxin induces endothelial cells to display 
fibroblast-like phenotypes resulting in endothelial fibrosis, but in the absence of an invoked 
immune response 53.  Nevertheless, it remains a possibility that other inflammation-related 
mechanisms may also lead to endothelial activation and injury.  In fact, an inflammatory 
response was observed with increasing endotoxin concentration in the current study.  
Specifically, increased hsCRP level was most evident beyond endotoxin concentration of 
2.50 EU/mL.  This finding is in keeping with the prior suggestion that clinically relevant 
endotoxemia exists at levels greater than 2.50 EU/mL 54.   Additionally, previous studies 
showed that endotoxin levels among healthy individuals, non-dialysis CKD, haemodialysis, 
and peritoneal dialysis patients were 0.01 EU/mL 19, 0.03 –  0.11 EU/mL 19,20, 0.64 - 0.69 
EU/mL 55, and 0.44 – 0.56 EU/mL 19,20 respectively.   The median endotoxin concentration 
level in the current cohort of KTRs was 1.95 EU/mL, substantially higher than those 
observed in healthy, non-dialysis and dialysis-dependent CKD populations.  Taken together, 
this study supports the concept that endotoxemia poses an increased cardiovascular risk in 
KTRs, extending the evidence-base from general and dialysis populations, and suggests the 
potential adverse impact of endotoxemia on cardiovascular outcomes.  Therefore, strategies 
aiming to reduce endotoxin levels among KTRs should be considered. 
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Hence, it can be hypothesised that modifying endotoxemia may represent a useful strategy in 
the management of inflammation and cardiovascular risk in kidney transplantation.  The 
findings from the earlier part of this study raise intriguing questions regarding possible 
interventions to combat endotoxemia.  The results presented in the latter part of this study 
proposed a number of such therapeutic options.  Firstly, lifestyle modification may be 
appropriate.  In particular, the positive associations between endotoxemia and saturated fat 
intakes as well as excessive fructose intakes may provoke intestinal bacterial dysbiosis 56-58, 
which in turn modulates intestinal tight junction integrity, increasing intestinal permeability 
and bacterial translocation, ultimately causing endotoxemia 59.  Therefore, minimising dietary 
intakes of saturated fats and fructose may be appropriate.  At present, recommendation on 
fructose intake in KTRs remains unavailable; results from the current study showed minimal 
effects of fructose intake on increasing endotoxemia and inflammation until it reaches 
approximately 75g per day.  These findings are in line with the general consensus that only 
excessive fructose consumption of ≥50 – 100g/day is associated with adverse health 
implications 60.  Secondly, the relationship between endotoxemia and increasing WC 
observed in the present study further supports the potential role of lifestyle intervention.  This 
relationship may be explained by the effect of diet-induced obesity or genetic obesity 61, 
whereby adverse changes in composition of gut microbiota were found in obese conditions, 
impairing gut barrier function, and hence promoting ‘metabolic endotoxemia’ 61.  Indeed, the 
mean WC measurements in the current cohort of KTRs were 105cm for males and 89cm for 
females, both of which were higher than the World Health Organisation cut-off points for risk 
of metabolic complications (>102cm for males; and >88cm for females) 62.  Therefore, 
strategies for targeting abdominal obesity among KTRs should be in place.  Finally, the 
independent association between endotoxemia and lower circulating levels of 25-
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hydroxyvitamin D suggests that dietary supplementation and sunlight exposure may be 
appropriate in this setting.  The inverse relationship between endotoxin and 25-
hydroxyvitamin D levels is supported by data existing outside the field of kidney 
transplantation, whereby vitamin D deficiency leads to defective gut mucosal integrity and 
immunity, allowing entry of endotoxin into the systemic circulation 63.  In addition, systemic 
clearance of LPS is impaired due to blunting of innate immunity by low circulating vitamin D 
level, resulting in endotoxemia 63.  Accordingly, findings from the current study serve to 
generate hypotheses amendable to future testing, with interventional studies required to 
explore these relationships in detail.  It is likely that the evaluation of enteric microbiome in 
kidney transplantation, which was outside the scope of the current study, may provide insight 
into the basic science of these findings. 
 
Of note, increased fructose intake, reduced 25-hydroxyvitamin D levels, and increased WC 
also displayed associations with inflammation independent of the relationship between 
endotoxemia and inflammation.  The mechanisms by which excessive fructose intake results 
in systemic inflammation are recognised 36, but the current study represents the first to 
describe this possible relationship in kidney transplantation.  Similarly, low vitamin D levels 
as possible drivers of inflammation has been described in other clinical settings 64,65, but not 
detailed in kidney transplantation.  The chronic systemic inflammation of obesity, originating 
from local immune responses in visceral adipose tissue 66, is recognised in kidney 
transplantation 12, and further confirmed in the current study.  Of interest, the reciprocal 
relationship between dietary fibre intake and inflammation in KTRs is a novel finding of this 
study; it was most evident when dietary fibre intake fell below 15g/day.  This relationship is 
consistent with findings from the general population 67-69.  Although the mechanism is 
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incompletely elucidated, it has been suggested that dietary fibre possibly decreases lipid 
oxidation and downstream inflammation 67. 
 
Finally, the association between reduced levels of adiponectin and endothelial activation is 
another novel and biologically plausible finding of this study.  It extends the recognised 
protective effects of adiponectin on endothelium from animal models and pre-clinical settings 
70,71 to kidney transplantation.  Other independent predictors of endothelial activation in this 
study, and perhaps testament to the face validity of the current findings, included the well-
recognised cardiovascular risk factors such as increased WC, male gender and raised blood 
pressure, with some evidence for an effect of aging and the use of CNI.  Of note, sE-selectin 
is considered the most specific circulating marker of endothelial health.  It reflects 
cotemporaneous endothelial activation rather than established structural vascular disease 43,72.  
In the context of kidney transplantation, structural vascular disease reflects a multiplicity of 
prior comorbidities including those accumulated during the period of CKD and dialysis, as 
well as ongoing endothelial injury 73.  Since the latter represented the focus of the current 
study, a specific endothelial activation marker (i.e. sE-selectin) was chosen for the analysis. 
 
Interestingly, the findings from this study showed that the use of statins did not have an 
impact on inflammation in KTRs.  The lack of anti-inflammatory effect may be accountable 
by the lack of lipid-lowering effect in this cohort of KTRs 74, as implicated by the mean 
levels of total- and LDL- cholesterol of 5.0 mmol/L and 3.1 mmol/L respectively, despite 
55% of the patient population were prescribed statin albeit at low doses.  In addition, 
smoking is known to promote inflammation and endothelial dysfunction 75.  It is somewhat 
surprising that tobacco use did not associate with markers of inflammation and endothelial 
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activation in the current cohort of KTRs.  Nevertheless, based on statistical point estimates, 
current smoker displayed positive associations with hsCRP, sE-selectin and endotoxin levels 
whereas ex-smoker revealed negative associations with hsCRP, sE-selectin and endotoxin 
levels.  The lack of observed statistical significance may be attributed to insufficient sample 
size with only 9% and 29% of smokers and ex-smokers respectively.  Also, such a 
discrepancy may be related to classification bias since ex-smokers in this study encompassed 
both distant and recent ex-smokers irrespective of their length of time since quitting.  Results 
from the National Health and Nutritional Examination Survey (NHANES III) showed that 
inflammation subsides only after 5 years of smoking cessation 76.  Therefore, the definition of 
“ex-smoker” employed in this study may not truly reflect the impact of tobacco exposure on 
inflammation and cardiovascular risk.  Previous studies investigating the adverse impact of 
smoking in CKD and kidney transplant populations sub-classified “ex-smokers” into “distant 
ex-smokers” (quitted smoking >1 or 5 years) or recent ex-smokers (quitted smoking <1 or 5 
years) 77-80.  Future studies aiming to evaluate the effects of smoking history on markers of 
inflammation and cardiovascular risk in KTRs should better delineate the “ex-smoker” 
category taking into account the duration of smoking cessation. 
 
This study has limitations that should be acknowledged.  It represents a single-centre 
observational experiment characterised by a small sample size and low cardiovascular event 
rates.  Therefore, further validations are needed in larger cohorts.   In addition, the use of 3-
day food diary may be influenced by day-to-day and seasonal variations.  The use of food 
frequency questionnaire should be included in future studies aiming to provide knowledge on 
habitual dietary intake over a longer period, enabling a more accurate assessment between the 
correlations of dietary intakes with inflammation, endothelial activation and endotoxemia.  
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Also, the studied cohort was predominately Caucasian, and hence the findings from this study 
may not be generalizable to other ethnic groups.  Furthermore, there is little variation in the 
use of immunosuppression, but such an effect helps to enhance the homogeneity of the study.  
Indeed, the R2 values generated from the multivariate statistical models demonstrate that the 
identified predictors are responsible for large proportions of the variation in outcome 
variables.  Soluble and cell surface expressed CD14 levels, both of which are influenced by 
endotoxemia 81, were not examined in the current study, therefore previous data 17,22-24 
describing their importance as exposures cannot be confirmed or refuted.  The cross-sectional 
nature of this study is unable to establish causality between predictor and outcome variables; 
long-term longitudinal follow-up and a detailed understanding of the basic science behind the 
observations found in this study is crucial. 
 
In summary, this study demonstrates potential targets for intervention, and sets the scene for 
future interventional research and therapeutic strategies in KTRs.  In particular, targeting 
endotoxemia may serve as a potent upstream intervention for the management of 
cardiovascular risk in these patients, potentially improving medium- and long- term clinical 
outcomes of kidney transplantation. 
 
Practical Application 
 
This study represents the first evidence in kidney transplantation showing that endotoxemia 
may be a significant independent predictor of inflammation and endothelial activation.  It 
provides preliminary insight into the association between endotoxemia and cardiovascular 
outcome in kidney transplantation.  Our findings highlight the potential relevance of 
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endotoxemia and other unconventional cardiovascular risk factors in kidney transplantation, 
setting the scene for future interventional research and therapeutic strategies.  
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Table 1.  Population Characteristics 
Demographic and Clinical Parameters 
Sample size (n) 128 
†Mean age (years) 49 ± 15 
Gender (%) Male = 56 Female = 44 
*Ethnicity (%) 
 
Caucasian = 78                
Afro-Caribbean = 5 
Asian = 15                     
Others = 2 
‡Median time post-transplantation (years) 4 (2-11) 
Pre-emptive transplantation (%) 22 
Number of kidney transplants (%) One = 92                        Two = 6                   Three = 2 
Dialysis vintage (days) 843 (414-1801) 
Smoking status (%) 
 
Non-smoker = 62 
Ex-smoker = 29 
Current smoker = 9 
‡Median alcohol intake (units/week) 1 (1-3)  
‡Median ICED score 2 (2-2) 
Presence of coronary heart disease 23%  
‡Median 7-year risk of MACE (%) 11 (6-19)  
5-year cardiovascular event rate [acute cardiovascular event] 
(number of patients and %) 
Number of patients = 6  % = 5 
‡Median follow-up duration for cardiovascular event (months) 51 (48-58)  
Presence of diabetes (%) 
 
Pre-DM = 10  
Non-diabetic = 75 
NODAT = 15 
Previous acute rejection episodes (%) Yes = 9 No = 91 
Immunosuppressive medication usage 
Prednisolone (%) 
Calcineurin inhibitor (%) 
Adjunctive antiproliferative agent (%) 
 
78 
91 
87 
Dosage of immunosuppressive medications 
‡Median dose of Prednisolone (mg/day) 
‡Median dose of Tacrolimus (mg/day) 
‡Median dose of Cyclosporin (mg/day) 
†Mean dose of Mycophenolate Mofetil (mg/day) 
†Mean dose of Azathioprine (mg/day) 
 
5 (5-5) 
4.0 (2.5-7.4) 
150 (150-200) 
1040 ± 402 
82 ± 36 
Lipid lowering medication usage 
Overall statin usage (%) 
Simvastatin (%) 
Atorvastatin (%) 
Fluvastatin (%) 
Pravastatin (%) 
 
55 
5 
7 
41 
2 
Dosage of lipid lowering medications 
‡Median dose of Simvastatin (mg/day) 
‡Median dose of Atorvastatin (mg/day) 
‡Median dose of Fluvastatin (mg/day) 
‡Median dose of Pravastatin (mg/day) 
 
30 (20-40) 
30 (10-40) 
40 (20-40) 
20 (10-20) 
Blood pressure 
†Mean SBP (mmHg) 
†Mean DBP (mmHg) 
†Mean MAP (mmHg) 
 
140 ± 19 
80 ± 11 
101 ± 11 
Laboratory Parameters 
†Mean urate (μmol/L) 420 ± 100 
‡Median 25-hydroxyvitamin D (nmol/L) 42 (20-64) 
†Mean eGFR (mL/min) 45 ± 18 
‡Median creatinine (µmol/L) 132 (107-169) 
Lipid profile 
†Mean total cholesterol (mmol/L) 
‡Median HDL (mmol/L) 
†Mean LDL (mmol/L) 
‡Median triglycerides (mmol/L) 
 
5.0 ± 1.1 
1.5 (1.2-1.9) 
3.1 ± 0.9 
1.5 (0.9-2.2) 
‡Median ACR (mg/mmol) 4.35 (1.63-14.7) 
‡Median hsCRP (mg/L) 2.47 (1.00-4.89) 
‡Median adiponectin (μg/mL) 10.25 (6.24-13.82) 
‡Median sE-selectin (ng/mL) 34.2 (24.1-44.8) 
‡Median endotoxin (EU/mL) 1.95 (1.49-2.38) 
Anthropometric Measurements and Body Composition Parameters 
†Mean BMI (kg/m2) All:  28.1 ± 5.7 Male:  29.1 ± 5.6 Female:  26.8 ± 5.8 
†Mean WC (cm) All:  98 ± 17 Male:  105 ± 16 Female:  89 ± 14 
Bio-impedance measurements 
†Mean LTI (kg/m2) 
†Mean FTI (kg/m2) 
†Mean volume expansion (%) 
 
All:  13.5 ± 3.8 
All:  13.8 ± 6.3 
All:  2.8 ± 7.8 
Dietary Intake Parameters 
‡Median fructose intake (g) 16.9 (9.0-26.7)  
‡Median dietary fibre intake (g) 15.8 (12.0-20.9)  
†Mean total fat intake (g) 82.9 ± 29.4  
‡Median saturated fat intake (g) 27.7 (19.5-36.1)  
*For the purpose of statistical analysis, the ethnicity of patients classified as “Afro-Caribbean”, “Asian” and “Others” was 
grouped as “Non-Caucasian”, 78% “Caucasian” versus 22% “Non-Caucasian”. 
†Normally distributed data, results expressed as mean ± standard deviation (SD). 
‡Non-normally distributed data, results expressed as median (interquartile range, IQR).  
Abbreviations:  ACR=Albumin-to-Creatinine Ratio; BMI=Body Mass Index; DBP=Diastolic Blood Pressure; 
eGFR=estimated Glomerular Filtration Rate; FTI=Fat Tissue Index; HDL=High-Density Lipoprotein; hsCRP=high-
sensitivity C-Reactive Protein; ICED=Index of Coexistent Disease; LDL=Low-Density Lipoprotein; LTI=Lean Tissue 
Index; MACE=Major Adverse Cardiac Events; MAP=Mean Arterial Pressure; NODAT=New Onset Diabetes After 
Transplantation; Pre-DM=Presence of Diabetes Mellitus pre-transplantation;  SBP=Systolic Blood Pressure; sE-
selectin=soluble E-Selectin; WC=Waist Circumference.	
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Table 2.  Predictors of Inflammation (hsCRP) in Kidney Transplant Recipients 
 Univariate Analysis Multivariate Analysis§ 
Ratioδ (95% CI∞) p-value Ratioδ (95% CI∞) p-value 
Laboratory Parameters 
**Adiponectin (μg/mL) 0.81 (0.22, 2.72) 0.72   
Endotoxin (EU/mL) 1.20 (1.07, 1.34) 0.002 1.20 (1.08, 1.33) 0.03 
**Vitamin D (nmol/L) 0.67 (0.49, 0.90) 0.004 0.82 (0.74, 1.00) 0.04 
**Urate (μmol/L) 1.11 (1.00, 1.22) 0.007   
**eGFR (mL/min) 0.74 (0.50, 1.22) 0.28   
HDL (mmol/L) 0.87 (0.74, 1.02) 0.08   
LDL (mmol/L) 1.13 (1.03, 1.23) 0.01   
*Total Cholesterol (mmol/L) 1.78 (0.80, 3.93) 0.15   
*Triglycerides (mmol/L) 1.97 (0.90, 4.31) 0.09   
Anthropometric Measurements and Body Composition Parameters 
*WC (cm) 1.12 (1.06, 1.16) <0.001 1.05 (1.02, 1.08) 0.002 
*FTI (kg/m2) 1.39 (1.23, 1.58) <0.001   
*LTI (kg/m2) 1.20 (0.96, 1.51) 0.11   
*Volume Expansion (%) 1.00 (0.90, 1.12) 0.95   
Dietary Intake Parameters 
*Fructose intake (g) 1.13 (1.12, 1.15) <0.001 1.12 (1.09, 1.13) <0.001 
*Dietary fibre intake (g) 0.85 (0.70, 0.90) <0.001 0.85 (0.79, 1.08) <0.001 
*Total fat intake (g) 0.82 (0.61, 1.11) 0.28   
*Saturated fat intake (g) 1.14 (1.10, 1.18) 0.03   
Demographic and Clinical Parameters 
**Age (years) 1.00 (0.55, 1.82) 0.95   
Gender 
Female 
Male 
 
1.00 
1.03 (0.87, 1.22) 
 
0.72 
  
†Ethnicity 
Caucasian 
Non-Caucasian 
 
1.00 
0.95 (0.84, 1.07) 
 
0.39 
  
**Time post transplantation (years)  1. 65 (0.50, 6.05) 0.38   
Pre-emptive transplantation 
No 
Yes 
 
1.00 
0.88 
 
0.21 
  
Previous episodes of acute rejection 
No 
Yes 
 
1.00 
1.15 (0.87, 1.54) 
 
0.32 
  
**Dialysis vintage (years) 1.05 (0.99, 1.07) 0.07   
ICED 1.13 (0.88, 1.44) 0.34   
Presence of diabetes 
Non-diabetic 
NODAT 
Pre-DM  
 
1.00 
1.11 (0.97, 1.26) 
1.15 (0.94, 1.39) 
 
0.12 
  
**MAP (mmHg) 1.11 (0.49, 2.23) 0.88   
Smoking status 
Non-smoker 
Ex-smoker 
Current smoker 
Ex-smoker / Current smoker 
 
1.00 
0.87 (0.72, 1.04) 
1.17 (0.87, 1.58) 
0.94 (0.79, 1.11) 
 
0.26 
  
Alcohol intake (units/week) 0.98 (0.96, 1.01) 0.24   
Use of statin 
No 
Yes 
 
1.00 
0.98 (0.82, 1.16) 
 
0.78 
  
Use of calcineurin inhibitor 
No 
Yes 
 
1.00 
0.83 (0. 62, 1.10) 
 
0.19 
  
Use of adjunctive antiproliferative agents 
No  
Yes 
 
 
1.00 
1.08 (0.95, 1.24) 
 
 
0.24 
  
Use of prednisolone 
No 
Yes 
 
1.00 
1.09 (0.89, 1.33) 
 
0.41 
  
Adjusted R2 from final model 67% 
§Results in the final multivariate regression model were presented. 
δDue to the logarithmic transformation of the outcome variable, exponential of the beta coefficient has been applied, and hence beta 
coefficient and its associated 95% CI have been transformed and reported in the form of “Ratio”.  For the categorical variable, the ratio of 
the outcome in each category was relative to the outcome in the baseline category.  For the continuous variable, unless otherwise stated, the 
ratio was given for one-unit increase in the explanatory variable. 
∞CI = Confidence Interval. 
†For the purpose of statistical analysis, the ethnicity of patients classified as “Afro-Caribbean”, “Asian” and “Others” was grouped as “Non-
Caucasian”, 78% “Caucasian” versus 22% “Non-Caucasian”. 
Abbreviations:  eGFR=estimated Glomerular Filtration Rate; FTI=Fat Tissue Index; HDL=High-Density Lipoprotein; hsCRP=high-
sensitivity C-Reactive Protein; ICED=Index of Coexistent Disease; LDL=Low-Density Lipoprotein; LTI=Lean Tissue Index; MAP=Mean 
Arterial Pressure; NODAT=New Onset Diabetes After Transplantation; Pre-DM=Presence of Diabetes Mellitus pre-transplantation; 
WC=Waist Circumference. 
(*) Coefficients reported for a 10-unit increase in explanatory variable. 
(**) Coefficients reported for a 100-unit increase in explanatory variable. 
 
Table 3.  Predictors of Endothelial Activation (sE-selectin) in Kidney Transplant Recipients 
 Univariate Analysis Multivariate Analysis§ 
Ratioδ (95% CI∞) p-value Ratioδ (95% CI∞) p-value 
Laboratory Parameters 
*Adiponectin (μg/mL) 0.94 (0.89, 0.98) 0.007 0.96 (0.92, 0.99) 0.004 
Endotoxin (EU/mL) 1.09 (1.05, 1.14) <0.001 1.04 (1.03, 1.05) 0.007 
**Vitamin D (nmol/L) 0.99 (0.90, 1.11) 0.85   
**Urate (µmol/L) 1.00 (0.97, 1.04) 0.46   
**hsCRP (mg/L) 1.49 (1.00, 2.22) 0.04 1.65 (1.11, 2.45) 0.02 
**eGFR (mL/min) 0.90 (0.82, 1.11) 0.51   
HDL (mmol/L) 0.93 (0.88, 0.99) 0.02   
LDL (mmol/L) 1.03 (0.99, 1.07) 0.06   
Total Cholesterol (mmol/L) 1.01 (0.98, 1.04) 0.37   
Triglycerides (mmol/L) 1.05 (1.02, 1.08) 0.001   
Anthropometric Measurements and Body Composition Parameters 
**WC (cm) 1.35 (1.11, 1.64) 0.003 1.35 (1.11, 1.65) 0.005 
**FTI (kg/m2) 1.22 (0.74, 2.01) 0.401   
LTI (kg/m2) 0.98 (0.97, 0.99) 0.004   
**Volume Expansion (%) 0.82 (0.55, 1.22) 0.44   
Dietary Intake Parameters 
**Fructose intake (g) 1.11 (1.00, 1.22) 0.04   
**Dietary fibre intake (g) 1.00 (0.61, 1.65) 0.93   
*Total fat intake (g) 1.11 (1.00, 1.22) 0.20   
*Saturated fat intake (g) 1.11 (0.82, 1.49) 0.44   
Demographic and Clinical Parameters 
**Age (years) 1.35 (1.11, 1.65) 0.006 1.22 (0.99, 1.49)  0.07 
Gender 
Female 
Male 
 
1.00 
1.09 (1.03, 1.16) 
 
0.004 
 
1.00 
1.07 (1.02, 1.13) 
 
0.01 
†Ethnicity 
Caucasian 
Non-Caucasian 
 
1.00 
1.02 (0.97, 1.07) 
 
0.41 
  
**Time post transplantation (years)  1.11 (0.67, 1.82) 0.66   
Pre-emptive transplantation 
No 
Yes 
 
1.00 
1.01 (0.94, 1.09) 
 
0.79 
  
Previous episodes of acute rejection 
No 
Yes 
 
1.00 
1.01 (0.91, 1.12) 
 
0.86 
  
**Dialysis vintage (years) 1.02 (0.97, 1.06) 0.15   
ICED 1.01 (0.92, 1.10) 0.85   
Presence of diabetes 
Non-diabetic 
NODAT 
Pre-DM  
 
1.00 
1.04 (0.99, 1.09) 
1.04 (0.96, 1.12) 
 
0.09 
  
**MAP (mmHg) 1.49 (1.11, 1.82) 0.006 1.35 (1.11, 1.82) 0.006 
Smoking status 
Non-smoker 
Ex-smoker 
Current smoker 
Ex-smoker / Current smoker 
 
1.00 
0.98 (0.92, 1.05) 
1.02 (0.92, 1.14) 
0.97 (0.91, 1.04) 
 
0.38 
  
Alcohol intake (units/week) 1.01 (0.99, 1.02) 0.38   
Use of statin 
No 
Yes 
 
1.00 
0.95 (0.90, 1.02) 
 
0.13 
  
Use of calcineurin inhibitor 
No 
Yes 
 
1.00 
1.15 (1.04, 1.28) 
 
0.008 
 
1.00 
1.09 (0.99, 1.20) 
 
0.06 
Use of adjunctive antiproliferative agents 
No  
Yes 
 
 
1.00 
1.01 (0.92, 1.10) 
 
 
0.91 
  
Use of prednisolone 
No 
Yes 
 
1.00 
1.03 (0.96, 1.11) 
 
0.41 
  
Adjusted R2 from final model 47% 
§Results in the final multivariate regression model were presented. 
δDue to the logarithmic transformation of the outcome variable, exponential of the beta coefficient has been applied, and hence beta 
coefficient and its associated 95% CI have been transformed and reported in the form of “Ratio”.  For the categorical variable, the ratio of 
the outcome in each category was relative to the outcome in the baseline category.  For the continuous variable, unless otherwise stated, the 
ratio was given for one-unit increase in the explanatory variable. 
∞CI = Confidence Interval. 
†For the purpose of statistical analysis, the ethnicity of patients classified as “Afro-Caribbean”, “Asian” and “Others” was grouped as “Non-
Caucasian”, 78% “Caucasian” versus 22% “Non-Caucasian”. 
Abbreviations:  eGFR=estimated Glomerular Filtration Rate; FTI=Fat Tissue Index; HDL=High-Density Lipoprotein; hsCRP=high-
sensitivity C-Reactive Protein; ICED=Index of Coexistent Disease; LDL=Low-Density Lipoprotein; LTI=Lean Tissue Index; MAP=Mean 
Arterial Pressure; NODAT=New Onset Diabetes After Transplantation; Pre-DM=Presence of Diabetes Mellitus pre-transplantation; 
WC=Waist Circumference. 
(*) Coefficients reported for a 10-unit increase in explanatory variable. 
(**) Coefficients reported for a 100-unit increase in explanatory variable. 
 
Table 4.  Predictors of Endotoxemia (Endotoxin) in Kidney Transplant Recipients 
 Univariate Analysis Multivariate Analysis§ 
Ratioδ (95% CI∞) p-value Ratioδ (95% CI∞) p-value 
Laboratory Parameters 
**Adiponectin (μg/mL) 0.74 (0.50, 1.10) 0.12   
**Vitamin D (nmol/L) 0.82 (0.74, 0.89) <0.001 0.90 (0.82, 0.97) <0.001 
**Urate (μmol/L) 1.04 (1.00, 1.11) 0.07   
**eGFR (mL/min) 1.01 (0.90, 1.11) 0.96   
*HDL (mmol/L) 0.51 (0.32, 1.22) 0.006   
*LDL (mmol/L) 1.67 (1.27, 2.20) <0.001   
*Total Cholesterol (mmol/L) 1.42 (1.12, 1.79) 0.004   
Triglycerides (mmol/L) 1.08 (1.06, 1.10) <0.001 1.06 (1.04, 1.08) <0.001 
Anthropometric Measurements and Body Composition Parameters 
**WC (cm) 1.22 (1.11, 1.49) 0.004 1.22 (1.11, 1.35) 0.01 
**FTI (kg/m2) 1.65 (1.11, 2.46) 0.02   
*LTI (kg/m2) 0.89 (0.84, 0.96) 0.002 0.95 (0.90, 1.00) 0.07 
**Volume Expansion (%) 0.90 (0.61, 1.22) 0.40   
Dietary Intake Parameters 
**Fructose intake (g) 1.11 (1.02, 1.22) <0.001 1.11 (1.01, 1.21) 0.01 
**Dietary fibre intake (g) 0.90 (0.61, 1.35) 0.55   
*Total fat intake (g) 1.00 (0.90, 1.11) 0.76   
*Saturated fat intake (g) 1.09 (1.06, 1.12) 0.04   
Demographic and Clinical Parameters 
**Age (years) 0.82 (0.74, 1.00) 0.09   
Gender 
Female 
Male 
 
1.00 
1.01 (0.95, 1.06) 
 
0.87 
  
†Ethnicity 
Caucasian 
Non-Caucasian 
 
1.00 
0.98 (0.94, 1.01) 
  
0.21 
  
**Time post transplantation (years)  0.90 (0.61, 1.35) 0.63   
Pre-emptive transplantation 
No 
Yes 
 
1.00 
0.97 (0.92, 1.04) 
 
0.08 
  
Previous episodes of acute rejection 
No 
Yes 
 
1.00 
1.01 (0.91, 1.08) 
 
0.85 
  
ICED 1.02 (0.94, 1.09) 0.70   
Presence of diabetes 
Non-diabetic 
NODAT 
Pre-DM  
 
1.00 
1.04 (0.98, 1.10) 
1.03 (0.99, 1.08) 
 
0.09 
 
1.00 
1.03 (0.99, 1.06) 
1.03 (0.99, 1.08) 
 
0.08 
**MAP (mmHg) 1.11 (0.90, 1.49) 0.21   
**Dialysis vintage (years) 1.01 (0.98, 1.09) 0.09   
Smoking status 
Non-smoker 
Ex-smoker 
Current smoker 
Ex-smoker / Current smoker 
 
1.00 
0.96 (0.91, 1.02) 
1.05 (0.96, 1.15) 
0.98 (0.93, 1.04) 
 
0.31 
  
Alcohol intake (units/week) 0.99 (0.98, 1.00) 0.14   
Use of statin 
No 
Yes 
 
1.00 
1.02 (0.96, 1.07) 
 
0.56 
  
Use of calcineurin inhibitor 
No 
Yes 
 
1.00 
1.01 (0.93, 1.11) 
 
0.75 
  
Use of adjunctive antiproliferative agents 
No  
Yes 
 
 
1.00 
1.02 (0.94, 1.10) 
 
 
0.69 
  
Use of prednisolone 
No 
Yes 
 
1.00 
0.99 (0.94, 1.06) 
 
0.87 
  
Adjusted R2 from final model 46% 
§Results in the final multivariate regression model were presented. 
δDue to the logarithmic transformation of the outcome variable, exponential of the beta coefficient has been applied, and hence beta 
coefficient and its associated 95% CI have been transformed and reported in the form of “Ratio”.  For the categorical variable, the ratio of 
the outcome in each category was relative to the outcome in the baseline category.  For the continuous variable, unless otherwise stated, the 
ratio was given for one-unit increase in the explanatory variable. 
∞CI = Confidence Interval. 
†For the purpose of statistical analysis, the ethnicity of patients classified as “Afro-Caribbean”, “Asian” and “Others” was grouped as “Non-
Caucasian”, 78% “Caucasian” versus 22% “Non-Caucasian”. 
Abbreviations:   eGFR=estimated Glomerular Filtration Rate; FTI=Fat Tissue Index; HDL=High-Density Lipoprotein; ICED=Index of 
Coexistent Disease; LDL=Low-Density Lipoprotein; LTI=Lean Tissue Index; MAP=Mean Arterial Pressure; NODAT=New Onset 
Diabetes After Transplantation; Pre-DM=Presence of Diabetes Mellitus pre-transplantation; WC=Waist Circumference. 
(*) Coefficients reported for a 10-unit increase in explanatory variable. 
(**) Coefficients reported for a 100-unit increase in explanatory variable. 
 
  






